This Penny Stock Has Wall Street's Attention and Is Up Nearly 600%

ImmunoPrecise Antibodies (IPA) shows strong technical momentum, hitting new 52-week highs on Aug. 21. The stock maintains a 100% “Buy” opinion from Barchart. Shares are up an impressive 565% in 2025. Despite bullish analyst sentiment, IPA is volatile and speculative.

Today’s Featured Stock

Valued at only $121 million, ImmunoPrecise Antibodies (IPA) is a technology platform company with end-to-end solutions empowering companies to discover and develop therapies against any disease.

What I’m Watching

I found today’s Chart of the Day by using Barchart’s powerful screening functions to sort for stocks with the highest technical buy signals; superior current momentum in both strength and direction; and a Trend Seeker “buy” signal. I then used Barchart’s Flipcharts feature to review the charts for consistent price appreciation. IPA checks those boxes. The Trend Seeker signaled a buy on Aug. 18.

More News from Barchart

Should You Buy the Dip as Palantir Stock Falls for 7 Straight Days? George Soros Is Betting Big on Beaten-Down UnitedHealth Stock. Should You? 2 ‘Strong Buy’ Stocks Offering Fat Yields of Over 7.5% in August 2025 Tired of missing midday reversals? The FREE Barchart Brief newsletter keeps you in the know. Sign up now!

IPA Price vs. Daily Moving Averages:www.barchart.com

Barchart Technical Indicators for ImmunoPrecise Antibodies

Editor’s Note: The technical indicators below are updated live during the session every 20 minutes and can therefore change each day as the market fluctuates. The indicator numbers shown below therefore may not match what you see live on the Barchart.comwebsite when you read this report. These technical indicators form the Barchart Opinion on a particular stock.

ImmunoPrecise Antibodies shares hit a new 52-week high on Aug. 21, touching $2.93 in intraday trading.

ImmunoPrecise Antibodies has a Weighted Alpha of +364.24. IPA has an 100% “Buy” opinion from Barchart. The stock gained 228.11% over the past year. IPA has its Trend Seeker “Buy” signal intact. ImmunoPrecise Antibodies is trading above its 20-, 50-, and 100-day moving averages. The stock made 7 new highs and gained 61.16% in the last month. Relative Strength Index (RSI) is at 67.62%. There’s a technical support level around $2.50.

Don’t Forget the Fundamentals

$121 million market capitalization. Revenue is projected to grow 17.58% this year and another 32.14% next year. Analysts expect IPA to report a per-share profit of $0.04 in 2027.

Analyst and Investor Sentiment on ImmunoPrecise Antibodies

I don’t buy stocks because everyone else is buying, but I do realize that if major firms and investors are dumping a stock, it’s hard to make money swimming against the tide.

Story Continues

It looks like Wall Street analysts are bullish on IPA, and so is Seeking Alpha.

The Wall Street analysts tracked by Barchart have issued 1 “Strong Buy,” 1 “Moderate Buy,” and 1 “Hold” opinion on the stock. Their price targets are between $3-$5. CFRA’s MarketScope Advisor gives the stock a “Buy” rating. Morningstar thinks the stock is 34% overvalued. 2,300 investors monitor the stock on Seeking Alpha, which rates the stock a “Strong Buy” based on their quant model

The Bottom Line on ImmunoPrecise Antibodies

IPA currently has momentum and is hitting new highs. Normally I would not feature a stock with only a $121 million market cap, ImmunoPrecise Antibodies has three Wall Street analysts in coverage.

I caution that IPA is volatile and even speculative in the current environment, which means investors should use strict risk management and stop-loss strategies.

Today’s Chart of the Day was written by Jim Van Meerten. Read previous editions of the daily newsletter here.

Additional disclosure: The Barchart of the Day highlights stocks that are experiencing exceptional current price appreciation. They are not intended to be buy recommendations as these stocks are extremely volatile and speculative. Should you decide to add one of these stocks to your investment portfolio it is highly suggested you follow a predetermined diversification and moving stop loss discipline that is consistent with your personal investment risk tolerance.

On the date of publication, Jim Van Meerten did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Barchart.com

View Comments